Ligand Pharmaceuticals Inc (LGND)

113.06
2.70 2.30
NASDAQ : Health Care
Prev Close 115.78
Open 115.66
Day Low/High 112.85 / 116.20
52 Wk Low/High 71.63 / 138.94
Volume 221.34K
Avg Volume 409.60K
Exchange NASDAQ
Shares Outstanding 20.85M
Market Cap 2.46B
EPS 13.00
P/E Ratio 10.77
Div & Yield N.A. (N.A)

Latest News

Ligand Initiates Phase 2 Trial With LGD-6972 In Type 2 Diabetes

Ligand Initiates Phase 2 Trial With LGD-6972 In Type 2 Diabetes

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announces the initiation of a Phase 2 clinical trial with the Company's glucagon receptor antagonist LGD-6972 for the treatment of type 2 diabetes mellitus (T2DM).

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease

Retrophin announced positive results from a study in which patients with a rare kidney disease responded to treatment with its experimental drug sparsentan.

Analysts' Actions -- ConocoPhillips, Discover, DineEquity, Maxim and More

Analysts' Actions -- ConocoPhillips, Discover, DineEquity, Maxim and More

Here are Wednesday's top research calls, including upgrades for ConocoPhillips and DineEquity, and downgrades for Discover and Maxim.

Ligand To Participate In Two Upcoming Investor Conferences

Ligand To Participate In Two Upcoming Investor Conferences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: Morgan Stanley Global Healthcare Conference...

Short Interest Falls 11% For LGND

Short Interest Falls 11% For LGND

The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 489,935 share decrease in total short interest for Ligand Pharmaceuticals Inc , to 3,981,742, a decrease of 10.96% since 07/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Results From Phase 1 Trials With Ligand's LGD-6972 In Type 2 Diabetes Mellitus Published In Diabetes, Obesity And Metabolism

Results From Phase 1 Trials With Ligand's LGD-6972 In Type 2 Diabetes Mellitus Published In Diabetes, Obesity And Metabolism

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announces that results from two Phase 1 clinical trials with LGD-6972, the company's investigational glucagon receptor antagonist, were published online in the August...

Trade-Ideas: Ligand Pharmaceuticals (LGND) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Ligand Pharmaceuticals (LGND) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Ligand Pharmaceuticals (LGND) as a weak on high relative volume candidate

Analysts' Actions -- FireEye, Kraft, Teva, U.S. Steel and More

Analysts' Actions -- FireEye, Kraft, Teva, U.S. Steel and More

Here are Friday's top research calls, including downgrades for FireEye and Teva Pharmaceuticals, and upgrades for Kraft Heinz and U.S. Steel.

Ligand Reports Second Quarter 2016 Financial Results

Ligand Reports Second Quarter 2016 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2016, and provided an operating forecast and program updates.

Ligand Announces Multi-Program LTP Technology Licensing Agreement With Nucorion Pharmaceuticals

Ligand Announces Multi-Program LTP Technology Licensing Agreement With Nucorion Pharmaceuticals

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of a license agreement for three programs utilizing Ligand's LTP (Liver Targeting Prodrug) technology with Nucorion Pharmaceuticals, Inc.

Trade-Ideas: Ligand Pharmaceuticals (LGND) Is Today's

Trade-Ideas: Ligand Pharmaceuticals (LGND) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Ligand Pharmaceuticals (LGND) as a "perilous reversal" (up big yesterday but down big today) candidate

Ligand To Report Second Quarter Results On August 4th

Ligand To Report Second Quarter Results On August 4th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report second quarter 2016 financial results on August 4, 2016.

SAGE Shares Surge After Postpartum Depression Drug Shows Promise

SAGE Shares Surge After Postpartum Depression Drug Shows Promise

Shares of SAGE Therapeutics jumped after the company reported data from its SAGE-547 clinical trial for the treatment of severe postpartum depression.

Ligand Enters Into OmniAb® Platform License Agreement With Gilead Sciences

Ligand Enters Into OmniAb® Platform License Agreement With Gilead Sciences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Gilead Sciences, Inc.

Ligand Receives $4 Million From Expansion Of Two OmniAb® License Agreements

Ligand Receives $4 Million From Expansion Of Two OmniAb® License Agreements

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that two recent events relating to its OmniAb platform generated $4 million in combined payments due to Ligand.

Insider Trading Alert - ATHN, LGND And ASPS Traded By Insiders

Insider Trading Alert - ATHN, LGND And ASPS Traded By Insiders

Stocks with insider trader activity include ATHN, LGND and ASPS

Ligand Reports First Quarter 2016 Financial Results

Ligand Reports First Quarter 2016 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2016, and provided an operating forecast and program updates.

Ligand Acquires Portfolio Of Synthetic Royalty And Milestone Rights From CorMatrix® Cardiovascular For $17.5 Million

Ligand Acquires Portfolio Of Synthetic Royalty And Milestone Rights From CorMatrix® Cardiovascular For $17.5 Million

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to multiple programs owned by CorMatrix ®.

Ligand Announces First Quarter 2016 Earnings Reporting Date And Participation In Four Upcoming Investor Conferences

Ligand Announces First Quarter 2016 Earnings Reporting Date And Participation In Four Upcoming Investor Conferences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces plans to report first quarter 2016 financial results prior to the opening of trading on May 4, 2016.

Revolade® Approved In EU As First In Class Therapy For Children Aged 1 Year And Above With Chronic ITP

Revolade® Approved In EU As First In Class Therapy For Children Aged 1 Year And Above With Chronic ITP

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the European Commission (EC) has approved Revolade® (eltrombopag), a Novartis product, for the treatment of pediatric (aged 1 year and above) chronic...

Ligand Enters Into OmniAb® Platform License Agreement With ABBA Therapeutics

Ligand Enters Into OmniAb® Platform License Agreement With ABBA Therapeutics

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with ABBA Therapeutics AG, a Swiss biotechnology company developing innovative immuno-oncology therapies.

Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval Of EVOMELA™ (melphalan) For Injection

Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval Of EVOMELA™ (melphalan) For Injection

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Spectrum Pharmaceuticals, Inc.

Ligand Reports Fourth Quarter And Full Year 2015 Financial Results

Ligand Reports Fourth Quarter And Full Year 2015 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2015, and provided an operating forecast and program updates.

Ligand Enters Into OmniAb® Platform License Agreement With Tizona Therapeutics

Ligand Enters Into OmniAb® Platform License Agreement With Tizona Therapeutics

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Tizona Therapeutics, Inc.

Ligand To Report Fourth Quarter And Full Year 2015 Results On February 10th

Ligand To Report Fourth Quarter And Full Year 2015 Results On February 10th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report fourth quarter and full year 2015 financial results on February 10, 2016.

These 2 Small-Cap Stocks Could Add Powerful Returns to Your Portfolio

These 2 Small-Cap Stocks Could Add Powerful Returns to Your Portfolio

The broader markets have been tanking, a fact that obscures the opportunities among selected small-cap rockets. We examine two of the most promising.